Charles Sande/Lancet Infect Dis

Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape.Mazur NI, Terstappen J, Baral R, Bardaji A, Beutels P, Buchholz UJ, Cohen C, Crowe JE, Cutland CL, Eckert L, Feikin D, Fitzpatrick T, Fong Y, Graham BS, Heikkinen T, Higgins D, Hirve S, Klugman KP, Kragten-Tabatabaie L, Lemey P, Libster R, Lowensteyn Y, Mejias A, Munoz FM, Munywoki PK, Mwananyanda L, Nair H, Nunes MC, Ramilo O, Richmond P, Ruckwardt TJ, Sande C, Srikantiah P, Thacker N, Waldstein KA, Weinberger D, Wildenbeest J, Wiseman D, Zar HJ, Zambon M, Bont L
Lancet Infect Dis, (2022). 23:e2-e21

Implementation strategies for passive respiratory syncytial virus immunisation.Sande CJ
Lancet Infect Dis, (2021). 21:1200-1201